Use of Indirect and Mixed Treatment Comparisons for Technology Assessment

Overview of attention for article published in PharmacoEconomics, September 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

policy: 2 policy sources

Readers on

mendeley: 122 Mendeley
citeulike: 2 CiteULike

Summary Policy documents

So far, Altmetric has seen 4 policy documents that reference this research output.

Vectibix for Left Sided Metastatic Colorectal Cancer – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: Committee papers

Cited by National Institute for Health and Care Excellence on 08 Mar 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: Assessment report

Cited by National Institute for Health and Care Excellence on 21 Dec 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Single Drug Technology Assessment Processes Across Health Technology Assessment Organizations

Cited by Canadian Agency for Drugs and Technologies in Health on 23 Sep 2015

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.